AstraZeneca

News

AstraZeneca makes a big RNA play, teaming up with VaxEquity

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19.

News

Coronavirus vaccine: how pharma is picking up the pace

Amnesty says COVID jab producers are causing human rights cr...

Amnesty International has slammed the six pharma companies behind the bulk of COVID-19 vaccine supplies for not agreeing to waive their intellectual property rights and share the technology

News

After Alexion buy, AZ plans $360m investment in Irish facili...

AstraZeneca has unveiled plans to build a brand new manufacturing facility at a site in Ireland operated by its recent acquisition Alexion, providing employment for around 100 workers inclu

News

ESMO21: Enhertu brings it’s A game to second-line breast can...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line r

News

ICER says Amgen's tezepelumab 'likely to be too expensive'

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not

News

MHRA clears third doses of AZ, Pfizer COVID jabs

The UK medicines regulator has cleared the use of a third dose of both the AstraZeneca and Pfizer COVID-19 vaccines, in readiness for a possible booster campaign ahead of the winter months.

AstraZeneca makes a big RNA play, teaming up with VaxEquity

Amnesty says COVID jab producers are causing human rights cr...

After Alexion buy, AZ plans $360m investment in Irish facili...

ESMO21: Enhertu brings it’s A game to second-line breast can...

ICER says Amgen's tezepelumab 'likely to be too expensive'

MHRA clears third doses of AZ, Pfizer COVID jabs

Germany said to be backtracking on pharma rebate changes

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks